Marinus Pharmaceuticals, Inc. Forecasted to Post Q1 2022 Earnings of ($0.94) Per Share (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNSGet Rating) – SVB Leerink lowered their Q1 2022 EPS estimates for Marinus Pharmaceuticals in a research report issued on Thursday, April 21st. SVB Leerink analyst M. Goodman now anticipates that the biopharmaceutical company will earn ($0.94) per share for the quarter, down from their previous forecast of ($0.91). SVB Leerink currently has a “Outperform” rating and a $27.00 target price on the stock. SVB Leerink also issued estimates for Marinus Pharmaceuticals’ Q3 2022 earnings at ($1.07) EPS, Q4 2022 earnings at ($1.07) EPS, FY2022 earnings at ($3.80) EPS, FY2023 earnings at ($3.35) EPS and FY2024 earnings at ($2.00) EPS.

Marinus Pharmaceuticals (NASDAQ:MRNSGet Rating) last announced its earnings results on Monday, March 21st. The biopharmaceutical company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.04. The company had revenue of $1.52 million for the quarter, compared to analysts’ expectations of $2.64 million. Marinus Pharmaceuticals had a negative return on equity of 121.57% and a negative net margin of 643.70%. During the same quarter in the prior year, the business earned ($0.55) earnings per share.

MRNS has been the topic of several other research reports. Truist Financial upped their price target on Marinus Pharmaceuticals from $35.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, March 22nd. Zacks Investment Research raised Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 26th. HC Wainwright reaffirmed a “buy” rating and set a $38.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, March 22nd. Cantor Fitzgerald upped their price target on Marinus Pharmaceuticals from $25.00 to $28.00 in a research note on Wednesday, April 20th. Finally, StockNews.com began coverage on Marinus Pharmaceuticals in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Marinus Pharmaceuticals has an average rating of “Buy” and a consensus price target of $29.86.

Shares of MRNS opened at $7.51 on Monday. The company has a quick ratio of 3.25, a current ratio of 3.25 and a debt-to-equity ratio of 0.83. Marinus Pharmaceuticals has a 12-month low of $7.10 and a 12-month high of $19.83. The firm has a market capitalization of $277.98 million, a PE ratio of -2.79 and a beta of 1.34. The stock’s fifty day simple moving average is $8.88 and its 200-day simple moving average is $10.47.

Several large investors have recently bought and sold shares of the stock. Walleye Capital LLC acquired a new stake in shares of Marinus Pharmaceuticals in the fourth quarter valued at approximately $125,000. Invesco Ltd. raised its holdings in Marinus Pharmaceuticals by 24.6% in the 3rd quarter. Invesco Ltd. now owns 14,644 shares of the biopharmaceutical company’s stock valued at $166,000 after acquiring an additional 2,889 shares in the last quarter. Virtus ETF Advisers LLC raised its holdings in Marinus Pharmaceuticals by 40.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 15,932 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 4,597 shares in the last quarter. Citigroup Inc. raised its holdings in Marinus Pharmaceuticals by 199.6% in the 3rd quarter. Citigroup Inc. now owns 16,863 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 11,234 shares in the last quarter. Finally, Trexquant Investment LP acquired a new position in Marinus Pharmaceuticals in the 3rd quarter valued at $193,000. Institutional investors and hedge funds own 85.95% of the company’s stock.

Marinus Pharmaceuticals Company Profile (Get Rating)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

See Also

Earnings History and Estimates for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.